Clinical Trials Logo

Tumor Progression clinical trials

View clinical trials related to Tumor Progression.

Filter by:
  • None
  • Page 1

NCT ID: NCT05553990 Recruiting - Clinical trials for Ischemic Stroke, Acute

Predictive Value of Human Microbiome and Serological Markers for Clinical Outcome of AIS With Active Cancer

Start date: June 7, 2020
Phase:
Study type: Observational

Explore with active cancer patients with acute ischemic stroke in the human body characteristic microorganism disorder to clinical prognosis of the predictive value of the secondary objective: to observe with active cancer patients with acute ischemic stroke in the body of microorganisms and their serological indexes change law of exploration condition change related biomarkers of microscopic objects group based on the human body.

NCT ID: NCT04370860 Completed - Tumor Progression Clinical Trials

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Start date: May 1, 2020
Phase:
Study type: Observational

To determine the optimal EGFR TKIs treatment strategies for lung adenocarcinoma harboring EGFR exon 19 deletion variants

NCT ID: NCT04018183 Completed - Tumor Progression Clinical Trials

The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer

Start date: April 19, 2019
Phase:
Study type: Observational

To understand the mechanism and cellular functions of PTK7-associated signaling pathways in promoting lung cancer progression and conferring treatment to epidermal growth factor receptor tysosine kinase inhibitors (EGFR TKIs).

NCT ID: NCT01959438 Recruiting - Malignant Tumor Clinical Trials

Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma

SECAR
Start date: February 2007
Phase: Phase 1/Phase 2
Study type: Interventional

In vitro studies have demonstrated that sodium selenite in sufficient concentration and during sufficient time have a high tumoricidal capacity. This is found in many human cell types as leukemia cells, mesothelioma and non-small cell lung cancer cells. A minority of cell lines seem to be resistant. The question from a clinical point of view is: Is it possible with respect to toxicity to administer sodium selenite to patients in sufficient dose and during sufficient time to get responses in patients with cancer? We have performed first part of phase-1 study and found MTD of 10.2 mg/m2 if given as 10 daily infusions during 12 days. We have recorded limited anti-tumor effect in this treatment regimen. However, in vitro data suggest that low concentration of continuous exposure for 51 h is much more effective. Now we are planning to continue the phase-I trial with modified protocol. More specific: 1. Phase I: Find maximal tolerable dose with continuous infusion 2. Phase II: Use MTD and study responses, if any